| scholarly article | Q13442814 |
| P2093 | author name string | Yang Liu | |
| David J Kwiatkowski | |||
| P2860 | cites work | Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints | Q24538300 |
| The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 | Q28145108 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer | Q28297155 | ||
| Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics | Q28298703 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 | Q28377992 | ||
| Cell cycle checkpoints: preventing an identity crisis | Q29547644 | ||
| Cell cycle checkpoint signaling through the ATM and ATR kinases | Q29617837 | ||
| Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924 | Q30410498 | ||
| Phosphatases reverse p53-mediated cell cycle checkpoints | Q33665426 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells | Q34000632 | ||
| A p53-dependent checkpoint pathway prevents rereplication | Q34533175 | ||
| Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. | Q34674350 | ||
| Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. | Q35858051 | ||
| Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells | Q36054977 | ||
| Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776 | Q37100166 | ||
| PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts | Q38449769 | ||
| Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor | Q39082437 | ||
| Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints | Q40443928 | ||
| Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells | Q43800235 | ||
| Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. | Q45234586 | ||
| Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. | Q47704520 | ||
| UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. | Q50537563 | ||
| Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. | Q52826586 | ||
| Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor | Q77556919 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 174-182 | |
| P577 | publication date | 2014-10-27 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target | |
| P478 | volume | 14 |
| Q37555069 | Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine |
| Q37699208 | Comprehensive analysis of aberrantly expressed profiles of lncRNAs and miRNAs with associated ceRNA network in muscle-invasive bladder cancer |
| Q52862875 | Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. |
| Q41017874 | Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma |
| Q28088334 | Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise |
| Q92222095 | Significance of TP53 mutation in bladder cancer disease progression and drug selection |
| Q38590471 | Targeted therapies in bladder cancer: an overview of in vivo research |
| Q38436074 | Tp53 and its potential therapeutic role as a target in bladder cancer |
| Q36292777 | Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer |
| Q92642815 | p21 in Cancer Research |
| Q64268069 | p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775 |
Search more.